• About us
• Contact

Advertisement

Organisation › Details

Monte Rosa Therapeutics AG

	Start	2018-01-01 established
	Group	Monte Rosa Therapeutics (Group)
	Industry	protein degradation technology
	Person	Warmuth, Markus (Monte Rosa Therapeutics 202009 CEO + Venture Partner at Versant Ventures before Eisai/H3 Biomedicine)
	Region	Basel BS
	Country	Switzerland
	Street	36 Aeschenvorstadt Labs at Technologiepark, Hochbergerstr. 60C, 4057 Basel
	City	4051 Basel
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		Record changed: 2026-04-25

Advertisement

More documents for Monte Rosa Therapeutics (Group)

• [1] Monte Rosa Therapeutics. (5/26/20). "Press Release: Monte Rosa Therapeutics Discloses $32.5 Million Financing. Launched from Versant’s Ridgeline Discovery Engine". Boston, MA & Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2026. Made in Germany.